REFERENCES

Adinoff B., Iranmanesh A., Veldhuis J.,et al. Disturbances of the stress response. The role of the HPA axis during alcohol withdrawal and abstinence. *Alcohol Health Res. World.* 1998; 22: 67-72.

Agarwal DP. Genetic polymorphisms of alcohol metabolizing enzymes. *Pathol Biol.* 2001; 49: 703-9.

Anton R.F.. What is craving models and implications for treatment. *Alcohol Research & Health.* 1999; 23: 165-73.

Auwerx J. and Staels B. Leptin. *Lancet.* 1998; 351: 737-42.

Bai Y, Zhang S, Kim KS, Lee JK, Kim KH. Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. *J Biol Chem* 1996; 271: 13939-42

Bates SH. and Myers Jr MG. The role of leptin receptor signaling in feeding and neuroendocrine function. *TRENDS Endocrinol Metab.* 2003; 14: 447-52.

Behn-Krappa A**,** Doerfler W**.** Enzymatic amplification of synthetic oligodeoxyribonucleotides: implications for triplet repeat expansions in the human genome. *Hum Mutat.* 1994; 3: 19-24.

Bernard B. Neuropeptides and Obesity. *Nutrition*. 2000; 16: 916-23.

Berridge K.C.. Food reward:brain substrates of wanting and liking. *Neurosci Biobehav Rev.* 1996; 20: 1-25.

Brady KT. and Sonne SC. The role of stress in alcohol use, alcoholism treatment, and relapse. *Alcohol Res Health*. 1999; 23: 263-71.

Brinkmann B., Klintschar M., Neuhuber F., et al. Mutation rate in human microsatellites:Influence of the structure and length of the tandem repeat. *Am. J. Hum. Genet.* 1998; 62: 1408-15.

Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein; evidence for a peripheral signal linking adiposity and central neural networks. *Science* 1995; 269: 546-9.

Caporaso N. Selection of candidate genes. *IARC Sci Publ*. 1999; 148: 23-36.

Casto RM, Vanness JM, Overton JM. Effects of central leptin administration on blood pressure in normotensive rats. *Neurosci Lett* 1998; 246: 29-32.

Cavalli-Sforza L.I. The DNA revolution in population genetics. *TIG.* 1998; 14: 60-65.

Chen Y-C, Lu R-B, Peng G-S, et al. Alcohol metabolism and cardiovascular response in an alcoholic patient homozygous for the ALDH2-2 variant gene allele. *Alcohol Clin Exp Res* 1999; 23(12): 1853-60.

Chiara GD. Alcohol and dopamine. *Alcohol Health Res World.* 1997; 21: 108-14.

Christos S. Mantzoros. The role of leptin in human obesity and disease: A review of current evidence. *Ann Intern Med.* 1999; 130: 671-680.

Costa A., Bono G., Martignoni E.,et al. An assessment of hypothalamo-pituitary-adrenal axis functioning in non-depressed, early abstinent alcoholics. *Psychoneuroendocrinology.* 1996; 21: 263-75.

Dai X., Thavundayil J., Gianoulakis C. Response of the hypothalamic-pituitary-adrenal axis to stress in the absence and presence of ethanol in subjects at high and low risk of alcoholism. *Neuropsychopharmacology.* 2002; 27: 442-52.

Davis K.L., Charney D.,et al. *Neuropsychopharmacology:The fifth generation of progress : an official publication of the American College of Neuropsychopharmacology* . 5th ed. Lippincott Williams & Wilkins. Philadelphia, 2002.

Debrauwere H., Gendrel C.G., Lechat S., et al. Differences and similarities between various tandem repeat sequences: Minisatellites and microsatellites. *Biochimie.* 1997; 79: 577-86.

Ellsworth D.L. and Manolio T.A. The emerging importance of genetics in epidemiologic research. I. Basic concepts in human genetics and laboratory technology. *AEP.* 1999; 9: 1-16.

Elmquist J.K.. Hypothalamic pathways underlying the endocrine, autonomic, and behavioral effects of leptin. *Physiology & Behavior.* 2001; 74: 703-8.

Enoch MA. and Goldman D. Problem drinking and alcoholism:Diagnosis and treatment. *Am Fam Physician.* 2002; 65: 441-8.

Esel E., Sofuoglu S., Aslan SS.,et al. Plasma levels of beta-endorphin, adrenocorticotropic hormone and cortisol during early and late alcohol withdrawal. *Alcohol & Alcoholism.* 2001; 36: 572-6.

Evans W.E. and Johnson J.A. Pharmacogenomics:The inherited basis for interdividual differences in drug response. *Ann. Rev. Genomics Hum. Genet.* 2001; 2: 9-39.

Farren CK. and Tipton KF. Trait markers for alcoholism:Clinical utility. *Alcohol & Alcoholism.* 1999; 34: 649-65.

Ferguson RA. and Goldberg DM. Genetics markers of alcohol abuse. *Clinica Chimica Acta.* 1997; 257: 199-250.

Flier J.S.. Commentary:Leptin expression and action:New experimental paradigms. *Proc. Natl. Acad. Sci.* 1997;94:4242-4245.

Frederich RC, Lollmann B, Hamann A, et al. Expression of obese mRNA and its encoded protein in rodents. Impact of nutrition and obesity. *J Clin Invest* 1995; 96: 1658-63.

Froehlich J.C. Opioid peptides. *Alcohol Health Res. World.* 1997; 21: 177-9.

Fuchs J. Alcoholism, malnutrition, vitamin deficiencies, and the skin. *Clin Dermatol* 1999; 17: 457-61.

Gary S.W. and Henry S. Relationship between Plasma Adrenocorticotropin, Hypothalamic Opioid tone, and Plasma Leptin. *J. Clin Endocrino Metab.* 1998; 83: 2138-42.

Gelehrter T.D. and Collins F.S. "Population genetics and multifactorial inheritance" in *Principles of medical genetics,* international ed. Williams & Wilkins Co., Philadelphia, pp.50-67, 1990.

Gianoulakis C. Alcohol-seeking behavior. The roles of the hypothalamic-pituitary-adrenal axis and the endogenous opioid system. *Alcohol Health Res. World.* 1998; 22: 202-10.

Gianoulakis C . Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. *J Psychiatry Neurosci.* 2001; 26: 304-18.

Giraffa G., Rossetti L. and Neviani E. An evaluation of chelex-based DNA purification protocols for the typing of lactic acid bacteria. *J. Microbiol. Methods.* 2000; 42: 175-84.

Gong DW, Bi S, Pratley RE, Weintraub BD. Genomic structure and promoter analysis of the human obese gene. *J Biol Chem.* 1996; 271: 3971-4.

Good D.J.. How tight are your genes?. *Horm Behav*. 2000; 37: 284-98.

Hagan M.M., Havel P.J., Seeley R.J.,et al. Cerebrospinal fluid and plasma leptin measurements:Covariability with dopamine and cortisol in fasting humans. *J Clin Endocrinol Metab.* 1999; 84: 3579-85.

Harada S., Agarwal DP, Goedde HW. Aldehyde dehydrogenase deficiency as cause of facial flushing reaction to alcohol in Japanese. *Lancet* 1982; 2(8253): 982.

Harbindar Jeet Singh. Editorial The Unfolding Tale of Leptin. *Malaysia Journal of Medical Sciences.* 2001; 8: 1-6.

Harris R.B.S. Leptin-Much more than a satiety signal. *Annu. Rev. Nutr.* 2000; 20: 45-75.

Hartwell L.H., Hood L., Goldberg M.L., et al. *Genetics from genes to genomes.* 2nd ed. McGraw-Hill Companies, Inc. New York, 2004.

Harvey J., Ashford MLJ. Leptin in the CNS:much more than a satiety signal. *Neuropharmacology.* 2003; 44: 845-54.

Hiller-Sturmhöfel S., Bartke A. The endocrine system. *Alcohol Health Res World.* 1998; 22: 153-64.

Hoffstedt J., Eriksson P., Mottagui-Tabar S.,et al. A polymorphism in leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. *Horm Metab Res.* 2002; 34: 355-9.

IOTF: the International Association for the Study of Obesity and the International Obesity Task Force. Global prevalence of Obesity. [Online]. Available. http://www.iotf.org/media/globalprev.htm [2005, September 10].

Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides-mediation of the actions of leptin. *Trends Neurosci* 1999; 22: 62-7.

Jenkins A.B., Markovic T.P., Fleury A., Campbell L.V. Carbohydrate intake and short-term regulation of leptin in humans. *Diabetologia*. 1997; 40: 348-51.

Karvonen MK., Pesonen U., Heinonen P.,et al.Identification of new sequence variants in the leptin gene. *J Clin Endocrinol Metab* 1998; 83: 3239-42.

Keightley PD, Lercher MJ and Eyre-Walker A. Evidence for widespread degradation of gene control regions in hominid genomes. *PLoS Biology.* 2005; 3: 282-8.

Kelada S.N., Eaton D.L., Wang S.S, et al. The role of genetic polymorphisms in environmental health. *Environ Health Perspect*. 2003; 111: 1055-64.

Kelly AE., Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. *J. Neurosci.*. 2002; 22: 3306-11.

Kendler KS, Davis CG, Kessler RC. The familial aggregation of common psychiatric and substance abuse disorders in the National Comorbidity Survey: a family history study. *Br J Psychiatry.* 1997; 170: 541-8.

Kiefer F., Jahn H., Jaschinski M.,et al. Leptin: A Modulator of Alcohol Craving? *Biol Psychiatry.* 2001; 49: 782-7.

Kiefer F., Jahn H., Schick M.,et al. Alcohol Intake, Tumour Necrosis Factor-α, Leptin and Craving:Factors of a Possibly Vicious Circle? *Alcohol & Alcoholism.* 2002; 37: 401-4.

Kiefer F., Jahn H., Schick M.,et al. Alcohol Self-administration, Craving and HPA-axis activity: an intriguing relationship. *Psychopharmacology.* 2002; 164: 239-40.

Kiefer F., Jahn H.,Wolf K.,et al. Free-choice alcohol consumption in mice after application of the appetite regulating peptide leptin. *Alcohol Clin Exp Res.* 2001; 25: 787-9.

Koob GF., Sanna PP., Bloom FE. Neuroscience of addiction. *Neuron.* 1998; 21: 467-76.

Korf B.R. : "Population Genetics" in *Human genetic a problem-based approach*, 2th ed. Blackwell Science, Inc., Massachusetts, pp.334-361, 2000.

Kraus T. , Reulbach U., Bayerlein K.,et al. Leptin is associated with craving in females with alcoholism. *Addicition Biology.* 2004; 9: 213-9.

Kwok P.Y. Methods for genotyping single nucleotide polymorphisms. *Annu. Rev. Genomics Hum. Genet.* 2001; 2: 235-58.

Mammes O., Betoulle D., Aubert R.,et al. Association of the G-2548A polymorphism in the 5'region of the *LEP* gene with overweight. *Ann Hum Genet.* 2000; 64: 391-4.

Mames O., Betoulle D., Aubert R., et al. Novel polymorphisms in the 5'region of the *LEP* gene. *Diabetes.* 1998; 47: 487-9.

Martina S.Z., Michal W.J.B., Peter W.,et al. Tumor necrosis factor increases serum leptin levels in humans. *J. Clin Endocrinol*. 1997; 82: 4080-7.

Mayer P. and Höllt V. Allelic and somatic variations in the endogenous opioid system of humans. *Pharmacol Ther.* 2001; 91: 167-77.

Meinders A.E., Toornvliet A.C., Pijl H.. Leptin. *Netherlands Journal of Medicine*. 1996; 49: 247-52.

Mizuno TM, Kleopoulos SP, Bergen HT, et al. Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting in ob/ob and db/db mice, but is stimulated by leptin. *Diabetes* 1998; 47: 294-7

Moffett S., Martinson J., Shriver MD., et al. Genetic diversity and evolution of the human leptin locus tetranucleotide repeat. *Hum Genet.* 2002; 110: 412-7.

Morash B, Wilkinson D, Murphy P, Ur Ehud, Wilkinson M.. Developmental regulation of leptin gene expression in rat brain and pituitary. *Mol Cell Endocrinol.* 2001; 185: 151–9.

Mueller R.F., Young I.D. *Elements of Medical Genetics,* 10th ed. Harcourt Brace and Company Ltd. New York, 1998.

Muy-Rivera M., Ning Y., Frederick IO.,et al. Leptin, soluble leptin receptor and leptin gene polymorphism in relation to preclampsia risk. *Physiol.Res.* 2005; 54: 167-74.

Nestler EJ. Molecular and cellular mechanisms of opiate and cocaine addiction. *Trends Pharmacol. Sci.* 2004; 25: 210-8.

Noble EP. Alcoholism and the dopaminergic system. *Addict Biol.* 1996; 1: 333-48.

Nussbaum R.L., McInnes R.R., Willard H.F.: "Genetic Variation in Individuals: Mutation and Polymorphism." In Genetics in medicine, 6th ed. W.B. Saunders Co., Philadelphia, pp. 79-94, 2001.

Oswald L.M., Wand G.S. Opioids and alcoholism. *Physiol Behav.* 2004; 81: 339-58.

Ott J. and Hoh J. Statistical multilocus methods for desequilibrium analysis in complex traits. *Hum. Mut.* 2001; 17: 285-7.

Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of Leptin,. *J Clin Endocrinol Metab* 1999; 84: 3686-95.

Paolo M.S., Rudolf L., Erik H.et al. Is there a role for the ob gene product leptin in essential hypertension. *AJH*. 1998; 11: 1305-11.

Peterson RJ, Goldman D, Long JC. Nucleotide sequence diversity in non-coding regions of ALDH2 as revealed by restriction enzyme and SSCP analysis. *Hum Genet* 1999; 104(2): 177-87

Petrakis I., Krystal J. Neuroscience:Implications for treatment. *Alcohol Health Res World.* 1997; 21: 157-60.

Radel M. and Goldman D. Pharmacogenetics of alcohol response and alcoholism:The interplay of genes and environmental factors in thresholds for alcoholism. *Drug Metab Dispos.* 2001; 29: 489-94.

Rehm J., Gmel G., Sempos CT.,et al. Alcohol-related morbidity and mortality. *Alcohol Res Health.* 2003; 27: 39-49.

Röjdmark S., Calissendorff J., Brismar K. Alcohol ingestion decreases both diurnal and nocturnal secretion of leptin in healthy individuals. *Clin Endocrinol.* 2001; 55: 639-47.

Rosenwasser AM. Alcohol, antidepressants, and circadian rhythms. *Alcohol Res Health*. 2001; 25: 126-35.

Ruth B.S. Harris. Leptin-much more than a satiety signal. *Annu. Rev. Nutr.* 2000; 20: 45-75.

Sandoval DA. and Davis SN. Leptin metabolic control and regulation. *J. Diabetes and Its Complications.* 2003; 17: 108-13.

Schlotterer C. and Tautz D. Slippage synthesis of simple sequence DNA. *Nucleic Acids Res.* 1992; 20: 211-5.

Schwartz MW, Seeley RJ, Woods SC, et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. *Diabetes* 1997; 46: 2119-23.

Self DW. and Nestler EJ. Relapse to drug-seeking: neural and molecular mechanisms. *Drug Alcohol Depend.* 1998; 51: 49-60.

Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. *Hypertension* 1998; 31: 409-14.

Shigemoto M., Nishi S., Ogawa Y.,et al. Molecular screening of both the promoter and the protein coding regions in the human *ob* gene in Japanese obese subjects with non-insulin-dependent diabetes mellitus. *Eur J Endocrinol.* 1997; 137: 511-3.

Shimabukuro M, Koyama K, Chen G., et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. *Proc Natl Acad Sci* 1997; 94: 4637-41

Shintani M., Ikegami H., Fujisawa T., et al. Leptin gene polymorphism is associated with hypertension independent of obesity. *J. Clin Endocrino Metab.* 2002; 87: 2909-12.

Shintani M., Ikegami H., Yamato E.,et al. A novel microsatellite polymorphism in the human OB gene: a highly polymorphic marker for linkage analysis. *Diabetologia*. 1996; 39: 1398–401.

Shrestha S., Smith M.W., Beaty T.H., et al. Theory and methodology for utilizing genes as biomarkers to determine potential biological mixtures. *Ann. Epidemiol.* 2005; 15: 29-38.

Stephanie F., Babara W., Peter S. Modulation of brain reward circuitry by leptin. *Science.* 2000; 287: 125-8.

Stewart RB. and Li TK. The neurobiology of alcoholism in genetically selected rat models. *Alcohol Health Res World.* 1997; 21: 169-76.

Strosberg AD. and Issad T. The involvement of leptin in humans revealed by mutations in leptin and leptin receptor genes. *TiPS.* 1999; 20: 227-30.

Stunff C.L., Christine LB., Nicholas JS.,et al. A common promoter variant of the leptin gene is associated with changes the relationship between serum leptin and fat mass in obese girls. *Diabetes*. 2000; 49: 2196-200.

Suh Y. and Vijg J. SNP discovery in associatin genetic variation with human disease phenotypes. *Mut. Res.* 2005; 573: 41-53.

Sweeney G. Leptin signaling. *Cellular Signaling.* 2002; 14: 655-63.

Swift R.M. Medications and alcohol craving. *Alcohol Res Health.* 1999; 23: 207-13.

Tomkins DM. and Sellers EM. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. *CMAJ.* 2001; 20: 817-21.

Tomasson HR, Edenburg HG, Crabb DW, et al. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. *Am J Hum Genet.* 1999; 65(3): 795-807.

Valenzuela CF. Alcohol and neurotransmitter interactions. *Alcohol Health Res World.* 1997; 21: 144-8.

Vernon R.G., Denis R.G.P., Sorensen A.. Signals of adiposity. *Domestic Animal Endocrinology.* 2001; 21: 197-214.

Walsh PS, Metzger DA, Higuchi R. Chelex ® 100, as a medium for simple extraction of DNA for PCR-based typing from forensic material. *Bio Techniques.* 1991; 10: 506-13.

Weigle DS, Bukowski TR, Foster DC, et al. Recombinant *ob* protein reduces feeding and body weight in the *ob/ob* mouse. *J Clin Invest.* 1995; 96: 2065-75.

White FJ. A behavioral/systems approach to the neuroscience of drug addiction. *J. Neurosci.* 2002; 22: 3303-5.

World Health Organization(WHO) (2005). *Alcohol and mental health.* [Online]. Available. ***http://www.euro.who.int/document/mnh/ebrief12.pdf*** [2005, January 10].

World Health Organization(WHO) (2004). WHO Global status report on alcohol 2004. [Online]. Available: **http://www.who.int/substance_abuse/publications/en/thailand.pdf** [2005, January 14].

World Health Organization(WHO). *The World health report 2002 : reducing risks, promoting healthy life.* Switzerland **:** World Health Organization**,** 2002.

Wise RA. Neurobiology of addiction. *Cur. Op Neurobiol.* 1996; 6: 243-51.

Yiannakouris N., Melistas L., Yannakoulia M.,et al. The –2548G/A polymorphism in the human leptin gene promoter region is associated with plasma free leptin levels; interaction with adiposity and gender in healthy subjects. *Hormones.0* 2003; 2: 229-36.

Yu WH., Kimura M., Walczewska A.,et al. Role of leptin in hypothalamic-pituitary function. *Proc. Natl. Acad. Sci.* 1997; 94: 1023-8.

Zernig G., Saria A., Kurz M., et al. *Handbook of Alcoholism*. CRC Press. New York., 2000.

กรมสุขภาพจิต กระทรวงสาธารณสุข. 2546. “สถานการณ์และแนวโน้มความเจ็บป่วยทางจิตของคนไทย”. [ระบบออนไลน์]. แหล่งที่มา **http://www.dmh.moph.go.th/trend.asp** [2004, January 15]

ธานินทร์ ภู่พัฒน์. *วิทยาการคิเอ็นเอในงานนิติเวช*. เชียงใหม่:ภาควิชานิติเวชศาสตร์ คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่, 2538.

ปราโมทย์ สุคนิชย์ มาโนช หล่อตระกูล. *DSM IV ฉบับภาษาไทย (ใช้รหัส ICD-10)*. พิมพ์ครั้งที่ 1. กรุงเทพฯ: โรงพิมพ์ชวนพิมพ์, 2539.

ภาณุพงศ์ จิตะสมบัติ. *ปัจจัยที่มีอิทธิพลต่อการดื่มและติดสุรา*. ขอนแก่น: ภาควิชาจิตเวชศาสตร์ มหาวิทยาลัยขอนแก่น, 2535.

วิชัย บุญแสง อัญชลี ทัศนาขจร ชัยณรงค์ วงศ์ธีรทรัพย์ นุสรา สิทธิดิลกรัตน์. *ลายพิมพ์ดีเอ็นเอจากสารพันธุกรรมสู่เทคโนโลยีพิสูจน์บุคคล*. พิมพ์ครั้งที่ 2. ปทุมธานี:ฝ่ายนิเทศน์สัมพันธ์ สำนักงานพัฒนาวิทยาศาสตร์และเทคโนโลยีแห่งชาติ, 2545.